Adverse Event Management with BCMA Therapy

Opinion
Video

Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
Related Content